457 related articles for article (PubMed ID: 25542807)
1. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
Wang XQ; Shen CL; Wang BN; Huang XH; Hu ZL; Li J
Gene; 2015 Mar; 558(2):200-7. PubMed ID: 25542807
[TBL] [Abstract][Full Text] [Related]
2. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
[TBL] [Abstract][Full Text] [Related]
3. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
[TBL] [Abstract][Full Text] [Related]
4. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
[TBL] [Abstract][Full Text] [Related]
5. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.
Simon T; Bhatt DL; Bergougnan L; Farenc C; Pearson K; Perrin L; Vicaut E; Lacreta F; Hurbin F; Dubar M
Clin Pharmacol Ther; 2011 Aug; 90(2):287-95. PubMed ID: 21716274
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.
Sridharan K; Kataria R; Tolani D; Bendkhale S; Gogtay NJ; Thatte UM
Indian J Pharmacol; 2016; 48(4):350-354. PubMed ID: 27756942
[TBL] [Abstract][Full Text] [Related]
8. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.
Price MJ; Murray SS; Angiolillo DJ; Lillie E; Smith EN; Tisch RL; Schork NJ; Teirstein PS; Topol EJ;
J Am Coll Cardiol; 2012 May; 59(22):1928-37. PubMed ID: 22624833
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.
Guo YM; Zhao ZC; Zhang L; Li HZ; Li Z; Sun HL
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27323099
[TBL] [Abstract][Full Text] [Related]
10. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C
Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042
[TBL] [Abstract][Full Text] [Related]
11. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH
Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793
[TBL] [Abstract][Full Text] [Related]
12. [Factors influencing platelet aggregation in patients with acute coronary syndrome].
Mazurov AV; Ziuriaev IT; Khaspekova SG; Iakushkin VV; Sirotkina OV; Ruda MIa
Ter Arkh; 2014; 86(9):83-9. PubMed ID: 25518511
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade.
Bonello L; Camoin-Jau L; Mancini J; Bessereau J; Grosdidier C; Alessi MC; Ostorero M; Dignat-George F; Paganelli F
Thromb Res; 2012 Jul; 130(1):70-4. PubMed ID: 22285300
[TBL] [Abstract][Full Text] [Related]
14. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G
Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404
[TBL] [Abstract][Full Text] [Related]
15. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
Namazi S; Kojuri J; Khalili A; Azarpira N
Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
[TBL] [Abstract][Full Text] [Related]
16. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
Karaźniewicz-Łada M; Danielak D; Rubiś B; Burchardt P; Oszkinis G; Główka F
J Clin Pharmacol; 2014 Aug; 54(8):874-80. PubMed ID: 24782221
[TBL] [Abstract][Full Text] [Related]
17. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
Pedersen RS; Nielsen F; Stage TB; Vinholt PJ; el Achwah AB; Damkier P; Brosen K
Clin Exp Pharmacol Physiol; 2014 Nov; 41(11):870-8. PubMed ID: 25115434
[TBL] [Abstract][Full Text] [Related]
18. Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS.
Peng L; Liu J; Qin L; Liu J; Xi S; Lu C; Yin T
Thromb Res; 2017 Sep; 157():97-102. PubMed ID: 28734158
[TBL] [Abstract][Full Text] [Related]
19. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375
[TBL] [Abstract][Full Text] [Related]
20. Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin.
Karaźniewicz-Łada M; Krzyżańska D; Danielak D; Rzeźniczak J; Główka F; Słomczyński M; Burchardt P
Eur J Clin Pharmacol; 2020 Mar; 76(3):419-430. PubMed ID: 31897532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
